Logo image of GV.PA

Genomic Vision (GV.PA) Stock Fundamental Analysis

EPA:GV - Euronext Paris - Matif - FR0011799907 - Common Stock - Currency: EUR

0.0018  +0 (+5.88%)

Fundamental Rating

0

Overall GV gets a fundamental rating of 0 out of 10. We evaluated GV against 72 industry peers in the Biotechnology industry. GV has a bad profitability rating. Also its financial health evaluation is rather negative. GV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GV has reported negative net income.
GV had a negative operating cash flow in the past year.
GV had negative earnings in each of the past 5 years.
In the past 5 years GV always reported negative operating cash flow.
GV.PA Yearly Net Income VS EBIT VS OCF VS FCFGV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -2M -4M -6M -8M

1.2 Ratios

GV has a worse Return On Assets (-268.44%) than 89.74% of its industry peers.
Industry RankSector Rank
ROA -268.44%
ROE N/A
ROIC N/A
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GV.PA Yearly ROA, ROE, ROICGV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GV.PA Yearly Profit, Operating, Gross MarginsGV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

GV does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GV has more shares outstanding
The debt/assets ratio for GV is higher compared to a year ago.
GV.PA Yearly Shares OutstandingGV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
GV.PA Yearly Total Debt VS Total AssetsGV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

GV has an Altman-Z score of -20.15. This is a bad value and indicates that GV is not financially healthy and even has some risk of bankruptcy.
GV has a Altman-Z score of -20.15. This is amonst the worse of the industry: GV underperforms 91.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -20.15
ROIC/WACCN/A
WACC5.63%
GV.PA Yearly LT Debt VS Equity VS FCFGV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 5M -5M 10M 15M

2.3 Liquidity

GV has a Current Ratio of 0.41. This is a bad value and indicates that GV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.41, GV is not doing good in the industry: 94.87% of the companies in the same industry are doing better.
GV has a Quick Ratio of 0.41. This is a bad value and indicates that GV is not financially healthy enough and could expect problems in meeting its short term obligations.
GV has a worse Quick ratio (0.36) than 94.87% of its industry peers.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.36
GV.PA Yearly Current Assets VS Current LiabilitesGV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

GV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.12%.
Looking at the last year, GV shows a small growth in Revenue. The Revenue has grown by 6.74% in the last year.
GV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -13.68% yearly.
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GV.PA Yearly Revenue VS EstimatesGV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M
GV.PA Yearly EPS VS EstimatesGV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GV.PA Price Earnings VS Forward Price EarningsGV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GV.PA Per share dataGV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06 -0.08 -0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Genomic Vision

EPA:GV (11/3/2023, 7:00:00 PM)

0.0018

+0 (+5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap693.19K
Analysts35
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -268.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-93.6%
ROA(5y)-88.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.31%
Cap/Sales 32.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.36
Altman-Z -20.15
F-Score3
WACC5.63%
ROIC/WACCN/A
Cap/Depr(3y)27.39%
Cap/Depr(5y)20.59%
Cap/Sales(3y)11.06%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.36%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.74%
Revenue growth 3Y-16.62%
Revenue growth 5Y-13.68%
Sales Q2Q%16.05%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.92%
OCF growth 3YN/A
OCF growth 5YN/A